Printer Friendly

NEORX RECEIVES FDA CLEARANCE TO BEGIN CLINICAL TESTING OF BONE MARROW PURGING PRODUCT

 NEORX RECEIVES FDA CLEARANCE TO BEGIN CLINICAL TESTING OF
 BONE MARROW PURGING PRODUCT
 SEATTLE, June 30 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) reported today that it has received permission from the Food and Drug Administration to begin clinical testing of OncoPurge, a proprietary product designed to eliminate tumor cells from the bone marrow of cancer patients who require autologous (self) bone marrow transplantation. The product consists of the company's NR-LU-10 antibody attached to Pseudomonas exotoxin, a highly potent protein toxin.
 OncoPurge initially will be studied in a phase I clinical trial using bone marrow harvested from patients with breast cancer who are scheduled to receive high dose chemotherapy. This treatment has a side effect of eliminating bone marrow function. Following chemotherapy, the harvested bone marrow will be returned to the patient to replace the damaged bone marrow. OncoPurge is used to kill the tumor cells in the harvested bone marrow before it is retuned to the patient. The study will be conducted in collaboration with investigators at the Fred Hutchinson Cancer Research Center and the Virginia Mason Medical Center, both located in Seattle.
 "This product is a further application of our targeted therapy technology," said Paul Abrams, M.D., J.D., president and CEO. "In in vitro studies, this toxin conjugate has been found to kill tumor cells selectively, while sparing normal marrow cells. OncoPurge may allow patients with advanced breast cancer to be treated."
 There are approximately 150,000 new cases of breast cancer annually in the United States. Approximately 50,000 cases are diagnosed as advanced breast cancer, and a high percentage of these have tumor cells in their bone marrow, which precludes aggressive treatment.
 The Fred Hutchinson Cancer Research Center is an independent, non- profit research institution internationally recognized for its work in bone marrow transplantation and the development of advanced medical technology to eliminate cancer and other potentially fatal diseases.
 Virginia Mason Cancer Center, a non-profit program of Virginia Mason Medical Center, is a regional caner treatment and diagnostic center serving the Northwest. The center also conducts a number of cancer research studies including clinical trials through the Community Clinical Oncology Program funded by the National Cancer Institute.
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA for two OncoTrac (R) cancer imaging products and has completed a phase III trial for a third imaging product. Targeted biopharmaceuticals to treat cancer, restenosis after angioplasty and autoimmune diseases are in pre-clinical testing.
 -0- 6/30/92
 /CONTACT: Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, 206-286-2519; Anthony J. Russo or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation ST: Washington IN: MTC SU:


SH-LR -- NY018 -- 5051 06/30/92 09:54 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1992
Words:480
Previous Article:BURNS PHILP RECEIVES OK ON DURKEE PURCHASE
Next Article:CRAWFORD AND COMPANY ANNOUNCES EARNINGS PROJECTION
Topics:


Related Articles
NEORX DEMONSTRATES EFFICACY IN ANIMALS OF TWO THERAPEUTIC PRODUCT LINES
NEORX REPORTS PROMISING EARLY RESULTS IN AVICIDIN CANCER THERAPY STUDIES
NEORX'S AVICIDIN ADVANCES IN PHASE I II CANCER THERAPY TRIALS
LEUKINE CLEARED BY FDA FOR USE IN ALLOGENEIC BONE MARROW TRANSPLANTATION
SPARTA PHARMACEUTICALS RECEIVES FDA CLEARANCE TO BEGIN HUMAN TESTING OF RETINOID WITH ORPHAN DRUG STATUS
IMMUNEX DRUG FIRST TO RECEIVE FDA CLEARANCE FOR USE WITH PERIPHERAL BLOOD PROGENITOR CELLS
NeoRx Updates Progress on Verluma(TM), Avidicin(TM) and Biostent(TM)
MedImmune and BioTransplant Announce Plans to Test MEDI-507 For Treatment of Graft-Versus-Host Disease; IND Submitted
NeoRx Begins Phase I Lymphoma Trial

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters